Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Myeloid cell-synthesized coagulation factor X dampens antitumor immunity.

Graf C, Wilgenbus P, Pagel S, Pott J, Marini F, Reyda S, Kitano M, Macher-Göppinger S, Weiler H, Ruf W.

Sci Immunol. 2019 Sep 20;4(39). pii: eaaw8405. doi: 10.1126/sciimmunol.aaw8405.

PMID:
31541031
2.

The tegument protein pp65 of human cytomegalovirus acts as an optional scaffold protein that optimizes protein uploading into viral particles.

Reyda S, Tenzer S, Navarro P, Gebauer W, Saur M, Krauter S, Büscher N, Plachter B.

J Virol. 2014 Sep 1;88(17):9633-46. doi: 10.1128/JVI.01415-14. Epub 2014 Jun 11.

3.
4.

Human cytomegalovirus pp71 stimulates major histocompatibility complex class i presentation of IE1-derived peptides at immediate early times of infection.

Hesse J, Reyda S, Tenzer S, Besold K, Reuter N, Krauter S, Büscher N, Stamminger T, Plachter B.

J Virol. 2013 May;87(9):5229-38. doi: 10.1128/JVI.03484-12. Epub 2013 Feb 28.

5.

Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.

Becke S, Aue S, Thomas D, Schader S, Podlech J, Bopp T, Sedmak T, Wolfrum U, Plachter B, Reyda S.

Vaccine. 2010 Aug 31;28(38):6191-8. doi: 10.1016/j.vaccine.2010.07.016. Epub 2010 Jul 23.

PMID:
20655401
6.

Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells.

Becke S, Fabre-Mersseman V, Aue S, Auerochs S, Sedmak T, Wolfrum U, Strand D, Marschall M, Plachter B, Reyda S.

J Gen Virol. 2010 Oct;91(Pt 10):2531-41. doi: 10.1099/vir.0.022293-0. Epub 2010 Jun 30.

PMID:
20592110
7.

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.

Mersseman V, Böhm V, Holtappels R, Deegen P, Wolfrum U, Plachter B, Reyda S.

Med Microbiol Immunol. 2008 Jun;197(2):97-107. doi: 10.1007/s00430-008-0085-2. Epub 2008 Mar 5.

PMID:
18320219
8.

Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies.

Mersseman V, Besold K, Reddehase MJ, Wolfrum U, Strand D, Plachter B, Reyda S.

J Gen Virol. 2008 Feb;89(Pt 2):369-79. doi: 10.1099/vir.0.83380-0.

PMID:
18198367
9.

Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity.

Reyda S, Sohn C, Klebe G, Rall K, Ullmann D, Jakubke HD, Stubbs MT.

J Mol Biol. 2003 Jan 31;325(5):963-77.

PMID:
12527302
10.

Trypsin mutants for structure-based drug design: expression, refolding and crystallisation.

Rauh D, Reyda S, Klebe G, Stubbs MT.

Biol Chem. 2002 Jul-Aug;383(7-8):1309-14.

PMID:
12437122
11.

pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design.

Stubbs MT, Reyda S, Dullweber F, Möller M, Klebe G, Dorsch D, Mederski WW, Wurziger H.

Chembiochem. 2002 Mar 1;3(2-3):246-9. No abstract available.

PMID:
11921406
12.

Supplemental Content

Support Center